In 2016, ROI for the top 12 pharmaceutical companies fell to just 3.7 percent. This sobering statistic is due to both declining pharmaceutical productivity (fewer drug approvals) and increasing research and development (R&D) costs. As the industry looks to the future, it is clear that it needs to consider how to offer the maximum value…